Siegfried invites its shareholders to the Annual General Meeting scheduled for 17 April 2019 in Zofingen. The agenda includes important motions.
Further Increased Distribution to Shareholders
The Board of Directors proposes a 20 cent increase in distribution to shareholders from capital contribution reserves to 2.60 francs per registered share.
Adjustment of Capital Structure
The Board of Directors proposes an ordinary increase of the share capital by means of increasing the nominal share value to CHF 27.00 without issuing new shares. As the share capital increase will be paid in from capital contribution reserves, the shareholders will not be subject to any contribution or other payment obligations. In addition, the Board of Directors proposes to create conditional share capital and authorized share capital of 215,000 shares each. This requires an amendment of the Articles of Incorporation. The conditional capital is reserved for the issuance of shares under the employee share participation programs of Siegfried Holding AG. The authorized share capital will allow the Company to flexibly and quickly seize acquisition or investment opportunities or to execute capital increases to optimize the shareholder structure.
Election of Rudolf Hanko to the Board
The Board of Directors proposes to elect Rudolf Hanko, Siegfried’s former Chief Executive Officer, to the Board of Directors. All of the current Board members, Ulla Schmidt, Colin Bond, Wolfram Carius, Reto Garzetti and Martin Schmid, stand for reelection. Andreas Casutt will again be proposed for the position of Chairman.
The invitation to Siegfried Holding AG’s Annual General Meeting, including the complete agenda and explanations of the Board of Directors plus additional information, is available at www.siegfried.ch/agm
Peter Gehler, Chief Communications Officer
Tel. +41 62 746 11 48
Mobile +41 79 416 41 16
Siegfried Holding AG
Untere Bruehlstrasse 4
Tel. +41 62 746 11 11
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2018, Siegfried reported annual sales of CHF 794.3 million and employs at the time being approximately 2350 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including aseptic filling.
Cautionary Statements Regarding Forward-Looking Statements
This press release may contain forward-looking statements based on current assumptions and forecasts made by Siegfried Group management and other information currently available to the Siegfried Group. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Siegfried Holding AG does not intend, and does not assume any liability whatsoever, to update these forward-looking statements or to conform them to future events or developments.